NeoGenomics (NASDAQ:NEO) Hits New 12-Month High – Here’s What Happened

Posted by George Bondi on Jun 29th, 2026

NeoGenomics, Inc. (NASDAQ:NEO – Get Free Report) shares hit a new 52-week high on Monday . The company traded as high as $14.35 and last traded at $14.1770, with a volume of 96414 shares changing hands. The stock had previously closed at $14.17.

Analyst Ratings Changes

Several research firms have issued reports on NEO. Weiss Ratings raised shares of NeoGenomics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 8th. Wall Street Zen raised shares of NeoGenomics from a “hold” rating to a “buy” rating in a research report on Saturday. TD Cowen lifted their price target on shares of NeoGenomics from $13.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, April 29th. William Blair reiterated a “market perform” rating on shares of NeoGenomics in a report on Monday, March 16th. Finally, Leerink Partners raised NeoGenomics from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $12.00 to $25.00 in a research note on Wednesday, April 29th. Six research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $13.86.

Read Our Latest Stock Analysis on NeoGenomics

NeoGenomics Trading Up 1.7%

The company has a quick ratio of 4.06, a current ratio of 4.42 and a debt-to-equity ratio of 0.41. The stock’s 50 day moving average is $9.81 and its two-hundred day moving average is $10.29. The company has a market capitalization of $1.88 billion, a PE ratio of -18.68 and a beta of 1.82.

NeoGenomics (NASDAQ:NEO – Get Free Report) last posted its earnings results on Tuesday, April 28th. The medical research company reported $0.01 EPS for the quarter, meeting analysts’ consensus estimates of $0.01. NeoGenomics had a negative net margin of 13.30% and a negative return on equity of 2.80%. The business had revenue of $186.67 million for the quarter, compared to the consensus estimate of $184.54 million. The company’s revenue for the quarter was up 11.3% compared to the same quarter last year. As a group, sell-side analysts predict that NeoGenomics, Inc. will post -0.15 EPS for the current fiscal year.

Insider Activity

In related news, Director Lynn A. Tetrault sold 5,307 shares of NeoGenomics stock in a transaction that occurred on Tuesday, June 9th. The shares were sold at an average price of $11.29, for a total transaction of $59,916.03. Following the transaction, the director directly owned 91,422 shares of the company’s stock, valued at $1,032,154.38. This trade represents a 5.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 1.10% of the company’s stock.

Hedge Funds Weigh In On NeoGenomics

A number of large investors have recently bought and sold shares of NEO. Amundi bought a new stake in NeoGenomics during the 1st quarter valued at $157,000. California State Teachers Retirement System raised its position in shares of NeoGenomics by 56.8% in the 1st quarter. California State Teachers Retirement System now owns 194,103 shares of the medical research company’s stock worth $1,440,000 after acquiring an additional 70,320 shares in the last quarter. Royal Bank of Canada raised its position in shares of NeoGenomics by 79.9% in the 1st quarter. Royal Bank of Canada now owns 32,433 shares of the medical research company’s stock worth $240,000 after acquiring an additional 14,402 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of NeoGenomics by 42.3% during the 1st quarter. The Manufacturers Life Insurance Company now owns 55,031 shares of the medical research company’s stock worth $408,000 after purchasing an additional 16,365 shares during the last quarter. Finally, Quantinno Capital Management LP lifted its stake in shares of NeoGenomics by 21.7% during the 1st quarter. Quantinno Capital Management LP now owns 49,291 shares of the medical research company’s stock worth $366,000 after purchasing an additional 8,796 shares during the last quarter. Institutional investors own 98.50% of the company’s stock.

NeoGenomics Company Profile

(Get Free Report)

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.